Program Description & Educational Objectives
In this activity, experts in the management of acute myeloid leukemia (AML) discuss how modern management strategies have been devised for younger and older adult patients, and how these strategies—which encompass chemotherapy, transplant, and targeted options—can be utilized to optimize patient outcome in both the upfront and relapsed/refractory settings.
Upon completion of this activity, participants will be able to:
- Test physician assumptions on the evidence-based management of adult acute myeloid leukemia (AML) in the newly diagnosed and relapsed settings, including for patients with high-risk features and advanced age
- Identify high-risk AML populations and individuals unlikely to benefit from standard cytotoxic treatment
- Demonstrate knowledge of new data on the safety and efficacy of novel cytotoxics and targeted agents across the spectrum of adult AML settings
- Select appropriate treatment for a given patient with newly diagnosed or relapsed AML, including standard or less intensive cytotoxic options, targeted therapy, transplant-based management, or enrollment in clinical trials, according to disease and patient characteristics
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, and other clinicians involved in the management of AML.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: August 11, 2010 - August 10, 2011
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Harry P. Erba, MD, PhD
Associate Professor of Internal Medicine
Department of Internal Medicine
Hematology and Oncology Division
University of Michigan Medical School
Ann Arbor, Michigan
Harry P. Erba, MD, PhD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Genzyme Corporation.
Grant/Research Support from Antisoma; Cephalon, Inc.; Chroma Therapeutics; Eli Lilly and Company; Gemin X; Genzyme Corporation; Kanisa Pharmaceuticals, Inc.; Millennium: The Takeda Oncology Company; Novartis Oncology; sanofi-aventis; Wyeth Pharmaceuticals Inc.; and Xanthus Pharmaceuticals, Inc.
Speakers Bureau participant with Celgene Corporation; Cephalon, Inc.; and Novartis Oncology.
Interviewee
Gary J. Schiller, MD
Professor, Department of Medicine
Director, Hematological Malignancy Stem Cell Transplantation Program
David Geffen School of Medicine at UCLA
Los Angeles, California
Gary J. Schiller, MD,
has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Aegera Therapeutics Inc.; Ambit Biosciences Inc.; Antisoma; Celgene Corporation; Millennium: The Takeda Oncology Company; and Novartis Oncology.
Speakers Bureau participant with Novartis Oncology.
CME Reviewer
Marc Zumberg, MD
Clinical Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Florida
Gainesville, Florida
Marc Zumberg, MD,
currently has no financial interests/relationships or affiliations in relation to this activity.
CNE Planner
Margaret Allee, RN, JD
Providence Health & Services
Portland, Oregon
Content Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education, Inc.
Carmine DeLuca
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
Amedco is an approved provider of continuing nursing education by the Wisconsin Nurses Association Continuing Education Approval Program Committee, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
The course is co-provided by Amedco and PVI, PeerView Institute for Medical Education. 0.5 contact hour(s).
Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.
This CME/CNE activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by Amedco.
This activity is supported by an educational grant from 
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
